Stryker Corporation (SYK)
What changed in recent filings
- Revenue +9% YoYQuarter ended Jun 30, 2026
- Institutions — 1 new · 3 added · 3 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Stryker Corporation recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 30, 2026Revenue +9.4% YoY · EPS $3.30Released after the close: Jul 30 close → Jul 31 close, the stock moved -6.4% · over the same window, market +0.7% · sector -0.5%
- 26Q1Released Apr 30, 2026Revenue +2.6% YoY · EPS $1.93Released after the close: Apr 30 close → May 1 close, the stock moved -6.5% · over the same window, market +0.3% · sector -1.0%
- 25Q4Released Jan 29, 2026Revenue +11.4% YoY · EPS $2.20Released after the close: Jan 29 close → Jan 30 close, the stock moved +4.3% · over the same window, market -0.3% · sector +0.0%
- 25Q3Released Oct 30, 2025Revenue +10.2% YoY · EPS $2.22Released after the close: Oct 30 close → Oct 31 close, the stock moved -3.5% · over the same window, market +0.3% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Stryker Corporation
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 7 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Stryker Corporation
Institutions we track that reported holding this stock in their most recent 13F.
- Fundsmith6.72% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.15% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management0.13% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)under 0.01% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.02% of portfolio · since 2020 Q1
- Point72 Asset Management0.15% of portfolio · since 2026 Q1
- Generation Investment ManagementNew this quarter1.57% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery. The company operates across MedSurg, Neurotechnology, and Orthopaedics, supplying hospitals, surgeons, and other healthcare providers with surgical equipment, endoscopic and communications systems, patient handling tools, emergency medical equipment, implantable devices, and neurovascular solutions. Its orthopaedics business includes implants used in joint replacement, trauma, and extremities procedures, while its medical and surgical portfolio addresses operating room efficiency, clinical workflows, and perioperative care. Stryker Corp. plays an important role in the global healthcare market by providing technologies that are used in surgery, acute care, and orthopedic treatment across a wide range of clinical settings.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Stryker Corporation is classified under the Biotech & Health sector. See peers below.
Stryker Corporation key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Stryker Corporation vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
SYK revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $6.6B, +9.4% YoY.
The largest segment is MedSurg and Neurotechnology, 55.0% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the MedSurg and Neurotechnology segment (about 56% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Stryker Corporation
Per SEC N-PORT · 2026-06-30 · by weight · factual
SYK on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
SYK FAQ
What is Stryker Corporation (SYK)?
Stryker Corp. is a medical technology company focused on products and services that support patient care and healthcare delivery. The company operates across MedSurg, Neurotechnology, and Orthopaedics, supplying hospitals, surgeons, and other healthcare providers with surgical equipment, endoscopic and communications systems, patient handling tools, emergency medical equipment, implantable devices, and neurovascular solutions. Its orthopaedics business includes implants used in joint replacement, trauma, and extremities procedures, while its medical and surgical portfolio addresses operating room efficiency, clinical workflows, and perioperative care. Stryker Corp. plays an important role in the global healthcare market by providing technologies that are used in surgery, acute care, and orthopedic treatment across a wide range of clinical settings.
What sector is Stryker Corporation in?
Stryker Corporation is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Stryker Corporation's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 8.5%, Operating margin 25.2%, Net margin 14.4%, ROE 3.8%, Debt-to-equity 0.59x. Definitions and interpretation are available on Stocklore.
What are Stryker Corporation's main revenue segments?
The largest segment is MedSurg and Neurotechnology, about 55.0% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Stryker Corporation (SYK) stock?
On Stocklore you can see SYK's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.